Khiron updates fully operational Colombian Lab Facilities (TSXV: KHRN)
Subsequent to my interview with Chris Naprawa, President of Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), the company issued an update of operations. The highlights are:
State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab includes full capabilities in Ultra high and High performance liquid chromatography ("UHPLC" & "HPLC") technology, gas chromatography, stability testing, microbiology and heavy metals testing.
Physical chemical cannabis testing lab has a capacity of up to 70 daily UHPLC & HPLC cannabinoid samples, 15 daily gas chromatography samples, and 2,000 monthly heavy metals samples. Microbiological testing lab has a capacity of up to 20 daily samples.
State-of-the-art testing lab allows the Company to fully test every aspect of its vertical integration from soil and water to flower to extract, ensuring a high-quality product that will be delivered to patients across Latin America.
Company reaffirms full grow site commercialization, starting with already approved CBD strains, anticipated in Q3 2019.
Cultivation capabilities operate within the most up-to-date country THC quotas assigned by the International Narcotics Control Board (INCB) to meet domestic demand, including to serve more than 119,000 patients at the Company's ILANS clinics.
Significant investment in cultivation and production facilities ensures capacity and infrastructure to meet the most stringent local testing requirements to sell in the Colombian market.